Search

everythinglearnresearchcommunity

for

Search:↓

Pyrilutamide 1% is being used for hair loss, with some users experiencing shedding but no regrowth yet. It may be too early to see results.

The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.

The conversation discusses using Pyrilutamide 1% as a potential treatment for hair loss, with some users combining it with minoxidil and finasteride. Experiences vary, with some reporting shedding and no progress, while others remain hopeful for future results.

A user shared their one-year progress with hair loss treatment, using topical minoxidil, 2% keto shampoo, microneedling, and finasteride. They plan to start dutasteride and are considering switching to oral minoxidil.

The conversation is about a user making a homemade topical dutasteride solution to use alongside testosterone replacement therapy (TRT) and oral dutasteride. The user aims to reduce DHT locally at the testosterone injection site and on the scalp.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

New hair loss treatments like stem cells, hair cloning, and gt20029 are unlikely to be available in the next 5-10 years, with some trials possibly starting by 2026. Current treatments like Minoxidil and Finasteride have been used for decades, and new developments depend on funding and successful trials.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

Pyrilutamide is considered by some as an alternative for those avoiding 5AR inhibitors like finasteride and dutasteride, but opinions on its effectiveness vary. Some users report similar results with fluridil and pyrilutamide, while others find pyrilutamide less effective compared to prescription treatments.

The user is considering whether to continue their hair loss treatment, which includes finasteride, minoxidil spray, keto shampoo, and dermarolling. Suggestions include increasing minoxidil application, adding multivitamins, improving sleep, and possibly switching to dutasteride, while the consensus is to keep going with the treatment.

A person considering finasteride for hair loss checked their hormone levels before starting treatment. They are concerned about the potential increase in estradiol and its effects, as well as the impact on their sex hormone-binding globulin (SHBG) and free testosterone levels.

People are using various treatments for hair loss, including dutasteride, finasteride, minoxidil (both oral and topical), RU58841, and ketoconazole shampoo. Some also use additional methods like microneedling, vitamins, and oils, with mixed results and personal preferences influencing their choices.

The user is considering minoxidil, clascoterone, and fluridil for hair loss, avoiding finasteride and RU58841. They are also contemplating a hair transplant and exploring the resilience of transplanted hair without finasteride.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

The conversation discusses a prescribed hair loss treatment combining 12.5% minoxidil with tretinoin, azelaic acid, and topical finasteride, costing $55 a month. One user criticizes the packaging for degrading tretinoin, another suggests it's an overpriced option and recommends topical dutasteride as an alternative due to its higher molecular weight and lower systemic absorption.

Minoxidil with alcohol and propylene glycol was more effective than non-alcohol versions, and RU58841 worked best in a non-water-based solution. Oral finasteride showed better results than topical, despite side effects; microneedling and tretinoin worsened hair loss, and PRP was only helpful when younger.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

A user took finasteride for six months, then switched to dutasteride for a year, increasing the dosage over time, but hair shedding worsened. Replies suggest the issue is male pattern baldness and DHT-related.

Koshine 826 (Pyrilutamide) is being used by several users to address hair loss, with mixed results on shedding and side effects. Some users report reduced shedding and no side effects, while others experience increased shedding and potential issues with libido and erectile dysfunction.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.

Obtaining treatments for hair loss that are not approved in one's own country, such as pyrilutamide or GT20029. It was suggested to use a middleman to get it, but there is the risk of getting low quality or fake products.

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.